4.6 Article

Paired box 5 increases the chemosensitivity of esophageal squamous cell cancer cells by promoting p53 signaling activity

期刊

CHINESE MEDICAL JOURNAL
卷 135, 期 5, 页码 606-618

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CM9.0000000000002018

关键词

PAX5; DNA methylation; Esophageal cancer; p53 signaling; Chemosensitivity

资金

  1. National Science Foundation of China (NSFC) [31671298, 81802390, 81672462]
  2. Natural Science Foundation of Beijing [7202187]
  3. National Key Research and Development Program of China [2016YFC0905200, 2016YFC0905302, 2017YFC 1308900]
  4. National Geriatrics Center Funding [NCRCG-PLAGH-2018002]
  5. Key Projects of Clinical Application and Promotion with Capital Characteristics [Z161100000516003]
  6. Military Medical Special Program for Youth of Chinese People's Liberation Army General Hospital [QNF19037]

向作者/读者索取更多资源

The PAX5 gene is downregulated by methylation in esophageal squamous cell carcinoma (ESCC) and has been found to inhibit cell proliferation, promote apoptosis, and activate the p53 signaling pathway. Restoring PAX5 expression can suppress tumor growth and increase chemosensitivity. PAX5 may serve as a potential marker for the chemosensitivity of ESCC.
Background: Gene promoter methylation is a major epigenetic change in cancers, which plays critical roles in carcinogenesis. As a crucial regulator in the early stages of B-cell differentiation and embryonic neurodevelopment, the paired box 5 (PAX5) gene is downregulated by methylation in several kinds of tumors and the role of this downregulation in esophageal squamous cell carcinoma (ESCC) pathogenesis remains unclear. Methods: To elucidate the role of PAX5 in ESCC, eight ESCC cell lines, 51 primary ESCC tissue samples, and eight normal esophageal mucosa samples were studied and The Cancer Genome Atlas (TCGA) was queried. PAX5 expression was examined by reverse transcription-polymerase chain reaction and western blotting. Cell apoptosis, proliferation, and chemosensitivity were detected by flow cytometry, colony formation assays, and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assays in ESCC cell lines with PAX5 overexpression or silencing. Tumor xenograft models were established for in vivo verification. Results: PAX5 methylation was found in 37.3% (19/51) of primary ESCC samples, which was significantly associated with age (P = 0.007) and tumor-node-metastasis stage (P = 0.014). TCGA data analysis indicated that PAX5 expression was inversely correlated with promoter region methylation (r = -0.189, P = 0.011 for cg00464519 and r = -0.228, P = 0.002 for cg02538199). Restoration of PAX5 expression suppressed cell proliferation, promoted apoptosis, and inhibited tumor growth of ESCC cell lines, which was verified in xenografted mice. Ectopic PAX5 expression significantly increased p53 reporter luciferase activity and increased p53 messenger RNA and protein levels. A direct interaction of PAX5 with the p53 promoter region was confirmed by chromatin immunoprecipitation assays. Re-expression of PAX5 sensitized ESCC cell lines KYSE150 and KYSE30 to fluorouracil and docetaxel. Silencing of PAX5 induced resistance of KYSE450 cells to these drugs. Conclusions: As a tumor suppressor gene regulated by promoter region methylation in human ESCC, PAX5 inhibits proliferation, promotes apoptosis, and induces activation of p53 signaling. PAX5 may serve as a chemosensitive marker of ESCC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据